Q.B.I. Enterprises

Quark Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the discovery and development of novel RNA interference (RNAi) based therapeutics. The company focuses on creating treatments for conditions such as acute kidney injury and ocular diseases. Quark operates in the biopharmaceutical market, targeting both healthcare providers and patients in need of advanced therapeutic solutions. The business model revolves around the research and development of RNAi-based drugs, progressing through various clinical trial phases to ensure efficacy and safety. Revenue is primarily generated through partnerships, licensing agreements, and potential future sales of approved drugs. Quark's leading products include QPI-1002, currently in Phase III trials for the prevention of acute kidney injury following cardiac surgery, and QPI-1007, also in Phase III trials for ocular diseases. The company aims to leverage its proprietary RNAi technology to address unmet medical needs and improve patient outcomes.

Keywords: RNAi therapeutics, acute kidney injury, ocular diseases, clinical-stage, biopharmaceutical, Phase III trials, drug development, healthcare providers, licensing agreements, proprietary technology.